Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples from Patients with Non-Small Cell Lung Cancer Treated with Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.
Archives of pathology & laboratory medicine（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined